Monlunabant在肥胖患者中的中期研究结果公布后，诺和诺德股价下跌-动脉网

Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients

benzinga 等信源发布 2024-09-20 12:24



可切换为仅中文







Friday, Novo Nordisk A/S NVO announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.

星期五，诺和诺德A/S NVO宣布了使用小分子口服大麻素受体1（CB1）反向激动剂monlunabant进行2a期临床试验的主要结果。

Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. for $1.075 billion, announced in August 2023.

Monlunabant，原名INV-202，是2023年8月宣布以10.75亿美元收购Inversago Pharmaceuticals Inc.的一部分。

Also Read: European Drug Agency Supports Novo Nordisk’s Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure.

另请阅读：欧洲药品管理局支持诺和诺德的重磅减肥药Wegovy治疗肥胖相关的心力衰竭。

The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg, and 50 mg of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome.

。

From a baseline body weight of 110.1 kg, all doses of monlunabant achieved a statistically significant weight loss compared to placebo.

从基线体重110.1公斤开始，与安慰剂相比，所有剂量的monlunabant均实现了统计学上显着的体重减轻。

After 16 weeks of treatment, people treated with a once-daily 10 mg dose of monlunabant achieved a weight loss of 7.1 kg compared to a reduction of 0.7 kg with a placebo.

经过16周的治疗，每天服用一次10毫克剂量的monlunabant的患者体重减轻了7.1公斤，而服用安慰剂的患者体重减轻了0.7公斤。

Limited additional weight loss was seen at higher doses of monlunabant.

较高剂量的monlunabant可以看到有限的额外体重减轻。

The most common adverse events in the trial were gastrointestinal, with the vast majority being mild to moderate and dose-dependent.

试验中最常见的不良事件是胃肠道，绝大多数是轻度至中度和剂量依赖性的。

Reporting of mild to moderate neuropsychiatric side effects, primarily anxiety, irritability, and sleep disturbances, was more frequent and dose-dependent with monlunabant compared to placebo.

与安慰剂相比，报告轻度至中度神经精神副作用（主要是焦虑，烦躁和睡眠障碍）的频率更高，并且与安慰剂相比具有剂量依赖性。

No serious adverse events were reported about neuropsychiatric side effects.

没有关于神经精神副作用的严重不良事件的报道。

Based on the results, Novo Nordisk expects to initiate a larger phase 2b trial in obesity in 2025 to further investigate dosing and the safety profile of monlunabant over a longer duration in a global population.

根据研究结果，诺和诺德预计将于2025年启动一项更大规模的肥胖2b期试验，以进一步调查蒙鲁那班在全球人群中更长时间的剂量和安全性。

Earlier this week, NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases.

本周早些时候，NanoVation Therapeutics宣布与诺和诺德建立多年合作伙伴关系，以推动针对心脏代谢和罕见疾病的新型遗传药物的开发。

Novo Nordisk will receive a defined exclusive, worldwide license to use NanoVation’s LNP technology for the two lead programs. NanoVation will receive research funding and is eligible to receive up to approximately $600 million in up-front cash, potential milestone payments, and tiered royalties on future product sales..

诺和诺德将获得一份明确的全球独家许可证，将NanoVation的LNP技术用于这两个领先项目。NanoVation将获得研究资金，并有资格获得约6亿美元的预付现金、潜在的里程碑付款以及未来产品销售的分层版税。。

Price Action: NVO stock is down 5.49% at $127.48 at the last check on Friday.

价格走势：NVO股价在周五的最后一次检查中下跌5.49%，至127.48美元。